# Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults

> **NCT06500299** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Overweight and Obesity

## Interventions

- **DRUG:** HDM1002 100 mg QD
- **DRUG:** HDM1002 200 mg QD 12weeks
- **DRUG:** HDM1002 400 mg QD 12weeks
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06500299
- **Lead sponsor:** Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-15
- **Primary completion:** 2024-10-30
- **Final completion:** 2024-11-30
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2024-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06500299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06500299, "Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06500299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*